会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Pyridine-thiols for treatment of a follicular dermatosis
    • 用于治疗滤泡性皮肤病的吡啶硫醇
    • US06482839B1
    • 2002-11-19
    • US09145822
    • 1998-09-02
    • Carl R. Thornfeldt
    • Carl R. Thornfeldt
    • A61K314402
    • A61Q19/08A61K8/19A61K8/20A61K8/23A61K8/26A61K8/27A61K8/28A61K8/29A61K8/368A61K8/4933A61K31/00A61Q19/00A61Q19/02Y10S514/859
    • This invention provides compositions and methods for treatment of skin and mucous membranes suffering from a follicular dermatosis. The compositions include one or more pyridine-thiols and tautomers with attached metallic moieties. Administration of the compounds to aging skin and mucous membranes in topical formulations, either as the only active ingredient or in combination with other known active ingredients to treat a follicular dermatosis. Additional compositions for treating follicular dermatosis contain one or more sulfides and oxides of these same metallic ions, either alone or in combination with other molecules. Topical formulations containing both a pyridine-thiol and tautomers with attached metallic moiety and a metallic sulfide and/or metallic oxide effectively treat skin and mucous membranes suffering from a follicular dermatosis.
    • 本发明提供了治疗患有滤泡性皮肤病的皮肤和粘膜的组合物和方法。 组合物包括一种或多种具有连接的金属部分的吡啶硫醇和互变异构体。 在局部制剂中施用化合物以老化皮肤和粘膜,作为唯一的活性成分或与其它已知的活性成分组合以治疗滤泡性皮肤病。 用于治疗滤泡性皮肤病的附加组合物含有一种或多种这些相同金属离子的硫化物和氧化物,单独或与其它分子组合。 含有吡啶硫醇和具有连接的金属部分的互变异构体和金属硫化物和/或金属氧化物的局部制剂有效地治疗患有滤泡性皮肤病的皮肤和粘膜。
    • 10. 发明授权
    • Administration of skin medications by use of dicarboxylic acids and
derivatives
    • 使用二羧酸及其衍生物给药皮肤药物
    • US5326790A
    • 1994-07-05
    • US869920
    • 1992-04-16
    • Carl R. Thornfeldt
    • Carl R. Thornfeldt
    • A61K31/19A61K31/20A61K31/34A61K31/35A61K31/455A01N37/02A01N25/00
    • A61K31/19A61K31/20A61K31/34A61K31/35A61K31/455Y10S514/946Y10S514/947
    • The topical administration of therapeutic agents to a variety of disease conditions, both cutaneous and systemic, is enhanced by combining the therapeutic agents with dicarboxylic acids or analogs of such acids, which include mono- and dimercapto derivatives, salts, esters, amides and anhydrides. Preferred dicarboxylic acids are azelaic and dodecanedioic acids and their monoglyceride and sucrose salts. Preferred therapeutic agents are antiinflammatory compounds, antihistamine compounds, antineoplastic compounds, vitamin D and retinoid agents. Specific examples of some of these compounds are 5-fluorouracil, methotrexate, bleomycin, carmustine and nitrogen mustard. The acids and analogs of this invention enhance the penetration capabilities of the therapeutic agents and are thus effective in promoting the therapeutic effect of these agents inside diseased cells, particularly for diseases such as inflammatory skin diseases and premalignant and non-melanoma malignant skin tumors.
    • 通过将治疗剂与这些酸的二羧酸或类似物组合,其包括单和二巯基衍生物,盐,酯,酰胺和酸酐,可将治疗剂局部施用于多种疾病状况,包括皮肤和全身。 优选的二羧酸是壬二酸和十二烷二酸及其单甘油酯和蔗糖盐。 优选的治疗剂是抗炎化合物,抗组胺剂化合物,抗肿瘤化合物,维生素D和类视色素。 一些这些化合物的具体实例是5-氟尿嘧啶,甲氨蝶呤,博来霉素,卡莫司汀和氮芥。 本发明的酸和类似物增强治疗剂的渗透能力,因此有效地促进这些药物在病变细胞内的治疗效果,特别是对于疾病如炎症性皮肤疾病,恶化前和非黑色素瘤恶性皮肤肿瘤。